Because abnormalities of the immune system may be involved in the pathogenesis of idiopathic congestive cardiomyopathy (ICCM), we studied suppressor cell function in patients with ICCM. Previously described in vitro techniques were modified for optimal demonstration of concanavalin A (con A)-inducible suppressor activity by peripheral blood mononuclear cells (PBM). Baseline responses in the mixed leukocyte reaction (MLR) were similar for PBM from 16 normal subjects, eight patients with end-stage coronary artery disease (CAD), and 18 patients with ICCM. In the presence of autologous, con A-treated PBM, MLR responses were significantly suppressed for normals (geometric mean disintegrations/min decreasing from 36,308 to 4677; p < 0.001) and for CAD patients (25,703 decreasing to 50l1;p < 0.001). In contrast, autologous, con A-treated PBM from patients with ICCM failed to suppress MLR responses (30,902 increasing to 44,688; p < 0.005). Similar results were observed in mitogen stimulation experiments. Con A-treated PBM from a normal subject suppressed the MLR response of PBM from an ICCM patient.
IDIOPATHIC CONGESTIVE CARDIOMYOPA-THY (ICCM) is a diagnosis of exclusion that distinguishes low output congestive heart failure and biventricular dysfunction of unknown origin from cardiac disease attributable to systemic hypertension, coronary atherosclerosis, valvular lesions, metabolic disorders, toxic exposure, clinically recognizable collagen-vascular disease, or neuromuscular disease." 2 The frequent presentation of ICCM after resolution of an apparently common viral illness suggests that the pathogenetic mechanism may include an acquired immune response to some triggering agent. 3 Pathological cardiac findings commonly observed in patients with ICCM, including interstitial fibrosis, sparse lymphocytic or other mononuclear cellular infiltrates, and immunoglobulin deposition on sarcolemmal membranes, are consistent with this hypothesis. 4 Presumably, such an immune response would be directed toward intrinsic or acquired cardiac antigens, and, in light of recent experimental evidence,8 might represent failure of the patient's immune mechanisms to regulate this response appropriately.
A suppressor system mediated by T lymphocytes may govern the regulation of immune responses. Since Gershon's discovery in 1970 that lymphocytes could suppress immune activities of other lymphocytes,9 experimental studies have shown clearly that T-cell sup-pressors can actively inhibit a broad range of immunological 'functions, including B-cell synthesis of immunoglobulin,'0' 11 proliferative T-cell responses to allogeneic or mitogenic stimuli,'2 and development of T-cell cytotoxic potential for alloantigens. '3 To investigate suppressor function in patients with ICCM, we adapted the in vitro method developed by Rich and Rich;'4 in this assay murine splenic T-cells activated by concanavalin A (con A) were tested for ability to suppress autologous T-cell-mediated immune responses. In this study we report the inability of con A-activated peripheral blood mononuclear cells (PBM) obtained from patients with ICCM to suppress autologous cell responses to either allogeneic mixed leukocyte reaction (MLR) or mitogenic (con A) stimuli.
Materials and Methods Subjects
Three groups of subjects were studied. The first group included 16 healthy medical center employees, eight male and eight female, ranging in age from 20-54 years. The second included eight hospitalized patients, all male, ranging in age from 34-64 years, with congestive heart failure secondary to coronary artery disease (CAD) and old myocardial infarction. The third group included 18 patients, 11 male and seven female, ranging in age from 16-54 years, with congestive heart failure unassociated with coronary artery disease (50% or greater narrowing of luminal diameter), familial cardiomyopathy, history of rheumatic fever, inordinate alcohol consumption, vitamin deficiency, endocrine disorder, arthritic disease, skin rashes, pregnancy, irradiation or exposure to known toxins. Ten patients in the latter group had a history consistent with viral illness ("flu-like syndrome") before the onset of cardiac symptoms by an interval of 1 week-4 months. These 10 patients underwent suppressor cell studies as early as 3 months and as late as 7 years after the onset of their cardiac symptoms. No virologic studies were performed on these patients.
Patients with ICCM and CAD were comparable in clinical status in terms of New York Heart Association functional classification, and all were receiving therapeutic doses of digoxin, furosemide, and various nitrate preparations. None was receiving aspirin or corticosteroids, and none had evidence of infection at the time of study. All patients underwent cardiac catheterization and left ventricular angiography. All patients also underwent coronary arteriography, except seven in the ICCM group under age 27 years; in four of these patients, direct pathologic examination of the heart was made either at autopsy or at cardiac transplantation. Subjects from both patient groups had similar abnormalities of hemodynamics and left ventricular contraction. All CAD patients had greater than 90% luminal narrowing or occlusion of at least one major coronary vessel, while, as noted above, no ICCM patient had either historical, arteriographic or pathologic evidence of significant coronary disease (table 1) .
Isolation and Preparation of Peripheral Blood Mononuclear Cells
A diagram of our experimental method is shown in figure 1. PBM were separated from fresh heparinized venous blood by Ficoll-Hypaque density gradient centrifugation using a modification of the technique of Boyum."5 Cells were washed three times with calcium and magnesium-free Hank's balanced salt solution (HBSS) (GIBCO, Grand Island, New York), resuspended in medium 199 with Hepes buffer (GIBCO) containing 10% heat-inactivated pooled human blood type AB serum (199-AB), and separated into two aliquots. One aliquot, adjusted to a final concentration of 4 X 106 cells/ml, was used for the preparation of suppressor cells, and the other, suspended at 1.2 X 106 cells/ml, held at room temperature for use as responder cells in either the mitogen stimulation or MLR studies. One milliliter of antibiotic and antimycotic solution (GIBCO) was routinely added to 100 ml of any cell suspension.
The lymphocyte: monocyte ratio of these suspensions, as determined by monocyte esterase staining"' of representative samples, was approximately 4: 1 and did not differ substantially between any of the groups studied. Cell viability was determined by trypan blue dye exclusion before treatment with con A, after 48 hours of incubation with con A, and after 5-6 days in mitogen stimulation or mixed lymphocyte culture; cell viability was always 90% or greater.
Suppressor Activation
Suppressor activity was induced by the addition of con A (Sigma Chemical Company, St. Louis, Missouri) to cell suspensions at a final concentration of 60 ,ug/ml, followed by incubation for 48 hours at 370C in 5% CO2. At the end of this period mitomycin C (MC) was added to a final concentration of 25 mg/ml, and cell suspensions incubated an additional three hours at 37°C, washed three times in HBSS, and resuspended in 199-AB at 1.2 X 106/ml. Parallel cultures run in the absence of con A were also prepared for use as suppressor controls.
Mitogen Stimulation Studies
Replicate 0.1-ml samples of responder cells were dispensed into round-bottom microtest plates (96 At NUNC Denmark, Irvine Scientific, Irvine, California). We added 0.1 ml of either the con A-activated or control cells, and then 0.025 ml of con A (60 it/ml in media 199). Cultures were incubated for 5 days in humidified 5% CO2 atmosphere. For the last 16 hours of incubation, 1 ,uCi of 3H-thymidine (New England Nuclear, Boston, Massachusetts) was added to each cell. The cells were collected in a multiple automatic sample harvester and uptake of isotope-labeled thymidine measured in a liquid scintillation counter (Packard Instrument Company, Inc, Downers Grove, 
Mixed Lymphocyte Response
Replicate 0. l-ml samples containing equal volumes of responder cells and random donor allogeneic, MCtreated stimulator cells combined to make up 1.2 X IO' cells in 0.1 ml were dispensed into microtest plates. To these samples one then added either 0.1 ml of the responder's autologous con A-activated or nonactivated cells. Additionally, 1.2 X 105 responder cells were cultured alone. Cultures were incubated for 6 days and processed as described above. To observe the effect of different incubation times on the MLR, we conducted an experiment in which aliquot cultures were harvested at either 2, 3, 4, 5, 6 or 7 days. In separate experiments, con A-activated cells autologous to the stimulator were used in place of those autologous to the responder.
I2.1-con A Binding by PBM
Purified con A was labeled according to the method of Greenwood and Hunter.17 Labeled con A was separated from unbound 1261 by passage over a Sephadex G-25 column equilibrated with 5% a-methyl-D-mannoside (a MM) in 0.15 M phosphate buffer pH 7.6. The material was 90% precipitable with trichloracetic acid. PBM from two normals and two ICCM patients were incubated in 60 jig/ml con A trace-labeled with 6 ,g/ml of 261I-con A. The PBM were incubated 48 hours and one aliquot was washed three times and its radioactivity measured; another was washed six times and counted. A third aliquot was counted after an additional 2-hour incubation in 5% a MM.
Separation of Glass Wool-Adherent Cells
Cells adherent to glass were removed by incubating 5 ml of cell suspension (20 X 106 cells) in 10-ml plastic syringes packed with HBSS-equilibrated glass wool (Corning Glass Works, Corning, New York) for 30 minutes at 37°C. Cells were eluted with 20 ml HBSS and readjusted to 4 X 108 cells/ml. Cell viability in all instances was greater than 90%.
Tabulation and Analysis of Data The arithmetic means (-SEM) and geometric means ( SEM) are given for the normal (A), CAD (B), and ICCM (C) groups.
Abbreviations: ni = dpm of responder cells alone; n2 = dpm of responder cells in the presence of allogeneic stimulator cells and autologous peripheral blood mononuclear cells (PBM) not activated with con A; and n3 = dpm of responder cells in the presence of allogeneic stimulator cells and autologous, con A-activated PBM.
Calculation of % suppression is explained in the text.
n3 represents dpm of responder cells in the presence of autologous con A-activated PBM, n2 the dpm of responder cells in the presence of autologous cells not activated with con A, and n1 the dpm of responder cells alone. The t test for paired or unpaired data was used to compare values from the three groups, where appropriate, after analysis of between-group variance. Within-group variability (SEM) for MLR and mitogen stimulation assays was 10% or less of the mean value.
Results

Suppression of MLR by Autologous Con A-Activated PBM
The effects of autologous con A-activated mononuclear cells on MLR for the three groups studied are summarized in tables 2A-C. In the presence of ur.treated autologous mononuclear cells, the MLR values of the three study groups did not differ significantly ( fig. 2 ). In the presence of con Aactivated PBM, normal and CAD MLR values were significantly suppressed from control levels The effect of harvesting the MLR at different times is represented in figure 4 . MLR of cells from a normal subject showed the expected stimulation of thymidine uptake occurring at 4-6 days of culture, and clear suppression of this activity by the addition of con Atreated PBM. In the MLR of cells from a patient with ICCM, allogeneic stimulation of thymidine uptake occurred between 4-6 days, but the addition of con Atreated PBM resulted in a net increase rather than suppression of thymidine uptake. This experiment also demonstrates that harvesting of cultures at 6 days is representative of the trend observed throughout the culture periodthat marked suppression occurred in the normal subject, but not in the patient with ICCM.
Suppression of Mononuclear Cell Responses to Mitogen by Autologous Con A-Activated Cells
PBM responses to mitogen (con A) in the presence of untreated autologous PBM did not differ significantly between the three groups ( fig. 5 ). In the presence of con A-activated PBM, mitogen responses in normal subjects decreased from a geometric mean of 54,900 to 12,300 dpm and in CAD patients mitogen responses decreased from 52,500 dpm to 24,500 dpm (p < 0.02 for both decreases); in contrast, mitogen responses in ICCM patients showed an increase from 41,700 dpm to 44,668 (NS).
Con A Binding by Mononuclear Cells
As illustrated in table 3, the binding capacity of 125Icon A by PBM from two normal subjects and two patients with ICCM did not differ significantly. Residual radioactivity in the PBM fraction after 48 hours incubation at 37°C, multiple cell washings, and incubation with a MM did not vary between these two groups.
Glass Adherence of Mononuclear Cells
Passage of PBM over glass wool prevented con A from inducing suppressor activity in PBM of normal subjects. This abolition of response occurred regardless of whether the cells were passed over glass before or after treatment with con A (table 4).
Suppression of MLR by Homologous Con A-Activated PBM
Con A-activated mononuclear cells from one ICCM patient did not suppress the MLR of cells from a normal subject. However, con A-activated mononuclear cells from the normal subject could suppress the MLR of PBM from the patient with ICCM (table 5).
Discussion
As we have shown, con A-activated suppression of proliferative mononuclear cell responses to allogeneic or mitogenic stimulation can be demonstrated in normal subjects; this finding is similar to that reported previously by Shou and co-workers.'8 Suppression of in vitro immune responses of normal subjects was caused by the addition of either autologous or homologous con A-activated PBM at the initiation of cultures and was abrogated by removal of glass adherent cells from the putative suppressor population.
However, con A-activated cells from peripheral blood of patients with ICCM failed to suppress significantly allogeneic responses of either autologous or homologous PBM, and only slightly suppressed mitogenic responses of autologous PBM. Failure to manifest con A-induced suppressor activity cannot be attributed to specific medications taken by ICCM patients, since similarly medicated patients with ischemic cardiomyopathy exhibited normally inducible suppressor function. It is also unlikely that differences in either the lymphocyte:monocyte ratio or the con A binding characteristics of cells from patients with ICCM can account for the differences in The results of two representative experiments are tabulated, comparing 1251-con A binding by PBM of normal subjects (NI) and idiopathic congestive cardiomyopathy (ICCM) patients. PBM aliquots were incubated with '251-con A, washed three times, incubated and washed six times, or incubated with 1251-con A, washed, and incubated with a MM. Results are shown in dpm (mean SEM), and there is no significant difference between NI and ICCM for any of the three treatments. DAYS FIGURE 4. Time course ofsuppression of mixed leukocyte reaction (MLR) by autologous con A-activated peripheral blood mononuclear cells. Thymidine uptake in the MLR is expressed on a logarithmic scale on the ordinate as disintegrations per minute (dpm). Values are given for cultures harvested on various days as shown on the abscissa. suppressor activity between the three groups studied. The composition of PBM populations of all three study groups was similar in regard to lymphocyte: monocyte ratios, and there was no discernible difference in the binding of 1251-con A to PBM from normal subjects or ICCM patients.
The most striking difference in suppressor activity noted between patients with ICCM and subjects in the other two study groups was identified in MLR studies. Here, addition of putative suppressors from ICCM patients generally resulted in stimulation rather than suppression of responses in the presence of autologous cells. Findings in the mitogen stimulation study paralleled those of the MLR results, but there was considerable overlap of values observed in patients in the three study groups. The use in our study of a responder: suppressor: stimulator ratio of 1:2:1 in MLR, compared with the 1: 1: 1 ratio generally employed in previous studies,'4' "I appeared to enhance suppressor activity and therefore allowed clear separation of assay values obtained in patients with ICCM, compared with those observed in patients with ischemic myopathy or in normal subjects.
Several reasons may explain the failure of con A to induce suppressor activity in ICCM patients. These include: 1) absence or impairment of glass adherent cells necessary for mediation of a suppressor response; 2) absence or impairment of precursor cells required in addition to glass adherent cells for generation of a suppressor response, and 3) absence or dysfunction of cells responding to a suppressor signal. The last possibility could be excluded by the demonstration that ICCM patient responder cells could be suppressed in MLR by the addition of normal con Aactivated cells autologous with respect to the Suppressors through glass after con A activation " 37,709 32,358 16 Abrogation of suppressor cell function after passage through glass wool. Peripheral blood mononuclear cells (PBM) from a normal subject (no. 15) were tested as responder cells in the mixed leukocyte reaction (MLR). ni = dpm of responder cells alone; n2 = dpm of responder cells incubated in the presence of autologous PBM not activated with con A; and n3 = dpm of responder cells incubated in the presence of conA-activated PBM. Percent suppression is calculated from ni, n2, and n3 as explained in text. If PBM were passed through glass wool columns before or after con A activation, the suppressor effect noted in the control condition (without any glass wool passage) was abolished. stimulator cells. This finding indicates that ICCM responder cells can react appropriately to a con Ainduced suppressor signal. In contrast, PBM from patients with ICCM, similarly used in MLR as both stimulator and con A-activated suppressor populations, do not effect suppression of homologous normal responder cells, suggesting failure of a suppressor signal to be delivered.
Actual stimulation of responder thymidine uptake in the MLR, rather than suppression, may have been due to residual con A bound to the treated, washed PBM. As was shown in table 3, con A remained on PBM after 48 hours of treatment, and could be partially removed by continued washing. In the absence of a suppressor signal, thymidine uptake by ICCM responder cells may have been stimulated by small amounts of con A coming off the treated PBM during the MLR.
Further insight into the nature of the immune defect in ICCM. patients cannot be defined from the results of these studies. We have described an in vitro finding that may reflect an in vivo defect in suppressor cell function with important consequences in disease pathogenesis. Whether the presumed defect is acquired or genetically determined, or both, or is only an artifact of in vitro peripheral blood cell-con A interaction is unknown.
Further dissection of the mechanism responsible for Suppression of mixed leukocyte reaction (MLR) by autologous and by homologous peripheral blood mononuclear cells (PBM). For each MLR, the responder, suppressor (control or con A-activated PBM), and stimulator are denoted by normal (NI) or idiopathic congestive cardiomyopathy (ICCM) with the subject's identifying number as subscript. Mean dpm 1 SEM are tabulated as n3 (MLR in the presence of con A-activated PBM) and n2 (MLR in the presence of control PBM not activated with con A). Note that in row 6 con A-activated PBM of ICCM patient 18 were not able to suppress the MLR response of normal subject 13, but that in row 8, con A-activated PBM from normal subject 13 were able to suppress the MLR response of ICCM patient 18.
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the in vitro defect that we have described is required. In this regard, several experimental studies are of interest. Folch and Waksman have demonstrated in mice a suppressor population of glass-adherent cells which they have determined to be T-cells. 12 Sakane and Green have shown that con A-activated suppression of B-cell immunoglobulin synthesis in humans is modulated by T-cells.'9 Krakauer and co-workers have demonstrated in adult NZB mice, in which genetically determined autoimmune disease is manifest, that con A activation of autologous cells fails to suppress B-cell synthesis of immunoglobulin in subsequent cultures.20 This is in contrast to findings in young syngeneic NZB mice without disease, in which con A-induced suppressor activity is apparent and similar to that observed in normal mice.
Additional studies with this model have identified a soluble immune response suppressor substance (SIRS) in culture supernatants of con A-stimulated splenic cells21 that can prevent the development of disease when injected into aging NZB mice. 22 Whether the cellular defect in ICCM patients involves only T-cells and is analogous to the absence of con Aactivated suppressor function in adult NZB mice is an attractive, but conjectural hypothesis. In humans, lack of normal suppressor cell function has been reported in patients with active, untreated systemic lupus erythematosus.23 In an assay system very similar to ours, Hodgson, Wands and Isselbacher found a lack of con A-induced suppressor activity in patients with chronic active hepatitis.24 It is possible that all diseases with "autoimmune" or "immunologically aberrant" characteristics may have deficient suppressor cell activity. 25 Implication of the failure of PBM from ICCM patients to suppress proliferative responses as a component in the pathogenesis of cardiac disease is speculative.
The data reported in the present study, however, do permit the conclus-ion that assay of con A-induced suppressor activity differentiates idiopathic from ischemic congestive cardiomyopathy. There are many possible causes of congestive cardiomyopathy. In our study, we were careful to assign the term idiopathic only to those cases in which there was no evidence of a known cause of congestive cardiomyopathy, such as hypertension, alcoolism, connective tissue or endocrine abnormality, vitamin deficiency, irradiation or exposure to toxins. The history of a preceding "flulike syndrome" in 10 of our 18 patients is compatible with the hypothesis that many cases of ICCM are provoked by cardiotropic viruses. How the host reacts to such an infection may determine the course of the illness as much as the virulence of the infecting agent. The absence of inducible in vitro suppressor cell function probably represents a general finding common to many immune-related disorders and provides a clue for further research in the etiology of ICCM.
